Funding for this research was provided by:
Takeda Pharmaceutical Company (T-CiRA Joint Program)
Japan Agency for Medical Research and Development (the Core Center for iPS Cell Research)
Japan Society for the Promotion of Science (Grant-in-Aid for Young Scientists B)
Received: 13 March 2019
Accepted: 10 February 2020
First Online: 13 March 2020
: P.G. and A.H. are inventors on a filed patent (PCT/JP2019/027708) based on the delivery system, virus-like particle, production, and use for genome editing described here. Y.M., H.H., and N.I. are employees of Takeda Pharmaceutical Company. A.H. is a principle investigator (without salary) of the T-CiRA program funded by Takeda Pharmaceutical Company. All other authors declare no competing interests.